{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:40:27Z","timestamp":1789274427769,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ajog.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T17:34:51Z","timestamp":1520876091000},"page":"624.e1-624.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the\u00a0efficacy and safety of orally administered\u00a0VT-1161 in\u00a0the treatment of recurrent\u00a0vulvovaginal candidiasis"],"prefix":"10.1016","volume":"218","author":[{"given":"Stephen R.","family":"Brand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten P.","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Sobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nyirjesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schotzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Tavakkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2018.03.001_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","article-title":"Recurrent vulvovaginal candidiasis","volume":"214","author":"Sobel","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2018.03.001_bib2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2018.03.001_bib3","first-page":"11","article-title":"Subjective health status and health-related quality of life among women with recurrent vulvovaginal candidosis (RVVC) in Europe and the USA","author":"Aballea","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ajog.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/LGT.0b013e3181d85bb7","article-title":"Attitudes and experience of women to common vaginal infections","volume":"14","author":"Johnson","year":"2010","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1258\/0956462991914429","article-title":"Recurrent vulvovaginal candidiasis: why does it occur?","volume":"10","author":"Rodgers","year":"1999","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ajog.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMp048152","article-title":"Chronic vulvovaginal candidiasis","volume":"351","author":"Eschenbach","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2006.01235.x","article-title":"Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy","volume":"49","author":"Meyer","year":"2006","journal-title":"Mycoses"},{"key":"10.1016\/j.ajog.2018.03.001_bib8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/01.AOG.0000239103.67452.1a","article-title":"Causes of chronic vaginitis: analysis of a prospective database of affected women","volume":"108","author":"Nyirjesy","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/innovait\/inp212","article-title":"Management of psychosexual problems in primary care","volume":"3","author":"Rolfe","year":"2010","journal-title":"InnovAiT"},{"key":"10.1016\/j.ajog.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajog.2018.03.001_bib11","unstructured":"Diflucan [package insert]. Pfizer; New York, NY. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s051lbl.pdf. Accessed March 23, 2017."},{"key":"10.1016\/j.ajog.2018.03.001_bib12","unstructured":"Federal Drug Administration. FDA Drug Safety Communication: FDA to review study examining use of oral fluconazole (Diflucan) in\u00a0pregnancy. 2016. Available at: https:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm497656.htm>. Accessed November 2017."},{"key":"10.1016\/j.ajog.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.2015.17844","article-title":"Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth","volume":"315","author":"M\u00f8lgaard-Nielsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2018.03.001_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1067\/mob.2002.125897","article-title":"Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women","volume":"187","author":"Bauters","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ajog.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/AAC.00185-15","article-title":"Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis","volume":"59","author":"Garvey","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2018.03.001_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in\u00a0vitro activity against Candida glabrata and C krusei isolates clinically resistant to azole and echinocandin antifungal compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob Agents and Chemother"},{"key":"10.1016\/j.ajog.2018.03.001_bib20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bpobgyn.2014.07.006","article-title":"Recurrent vulvovaginitis","volume":"28","author":"Powell","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000314022","article-title":"Management of recurrent vulvo-vaginal candidosis as a chronic illness","volume":"70","author":"Donders","year":"2010","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ajog.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00006454-199211120-00017","article-title":"Congenital malformations in an infant born to a woman treated with fluconazole","volume":"11","author":"Lee","year":"1992","journal-title":"Pediatr Infect Dis"},{"key":"10.1016\/j.ajog.2018.03.001_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/JCM.03044-13","article-title":"Impact of new antifungal breakpoints on antifungal resistance in Candida species","volume":"52","author":"Fothergill","year":"2014","journal-title":"J\u00a0Clini Microbiol"},{"key":"10.1016\/j.ajog.2018.03.001_bib24","first-page":"238","article-title":"Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomology","volume":"3","author":"Mintz","year":"2013","journal-title":"Adv Inf Dis"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937818302072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937818302072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:18:38Z","timestamp":1757589518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937818302072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0002937818302072"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2018.03.001","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the\u00a0efficacy and safety of orally administered\u00a0VT-1161 in\u00a0the treatment of recurrent\u00a0vulvovaginal candidiasis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}